EUVIMEDEUVIMED entdecken
Crossref

Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes

Sachin H Bhagchandani iD, Stephen Ehrenzeller iD, Ivan S Pires iD, Namit Chaudhary iD, Carmen J Booth iD, Dong-Il Kwon iD, Charalampia Koutsioumpa iD, Christopher A Baker iD, Claire Laxton iD, Keyla Santos Guedes de Sá iD, Cullen Matthews iD, Priya Gill und 7 weitere

Science Immunology · 19.06.2026 · 11 (120)

DOI: 10.1126/sciimmunol.aea6419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 19.06.2026. Verfasst von Sachin H Bhagchandani und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Herpes Genitalis, Oligodeoxyribonucleotides, Nanoparticles, Adjuvants, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genital herpes, caused by herpes simplex virus 2 (HSV-2), remains a prevalent sexually transmitted infection with no available vaccine. Effective local immunity, mediated in part by tissue-resident memory T cells (T RM cells) and luminal antibodies, provides immediate viral control. Here, we developed bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) formed via electrostatic interactions between CpG oligodeoxynucleotides (CpG ODNs) and the chemokine CXCL9. This adjuvant enhances antigen-presenting cell engagement and innate immune signaling, promotes CD8 T cell recruitment, and reduces local neutrophilic inflammation relative to CpG ODNs. After intramuscular priming with HSV-2 glycoprotein-encoding messenger RNA–lipid nanoparticles, vaginal boosting with cognate recombinant glycoprotein and BEACONs improved protection against HSV-2 by increasing local CD8 T RM cell populations and mucosal antibody responses. Vaccine-mediated protection required local delivery of both antigen and adjuvant and was reduced by CD8 T cell or B cell depletion. These findings support engineered mucosal adjuvants for vaccines targeting genital herpes and other sexually transmitted infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes GenitalisOligodeoxyribonucleotidesNanoparticlesAdjuvants, ImmunologicHerpesvirus 2, HumanAnimalsFemaleImmunity, MucosalMiceNanovaccinesCD8-Positive T-LymphocytesVaccinationMice, Inbred C57BLAntibodies, Viral

Substanzen

OligodeoxyribonucleotidesAdjuvants, ImmunologicCPG-oligonucleotideNanovaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA.
  • Center for Infection & Immunity, Yale University School of Medicine, New Haven, CT 06520, USA.
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Center for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
  • Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.

ORCID-Profile: Sachin H Bhagchandani, Stephen Ehrenzeller, Ivan S Pires, Namit Chaudhary, Carmen J Booth, Dong-Il Kwon, Charalampia Koutsioumpa, Christopher A Baker, Claire Laxton, Keyla Santos Guedes de Sá, Cullen Matthews, Andrew Hudak, Rafael Bayarri-Olmos, William Brenham Hooper, Akiko Iwasaki

Förderung

  • Howard Hughes Medical Institute

Zitieren

APA

Bhagchandani, S. H., Ehrenzeller, S., Pires, I. S., Chaudhary, N., Booth, C. J., Kwon, D. I., Koutsioumpa, C., Baker, C. A., Laxton, C., Santos Guedes de Sá, K., Matthews, C., Gill, P., Li, S., Olszowka, A., Hudak, A., Fischer, S., Bayarri-Olmos, R., Hooper, W. B., & Iwasaki, A. (2026). Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Science Immunology, 11(120). https://doi.org/10.1126/sciimmunol.aea6419

Vancouver

Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, et al. Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Science Immunology. 2026;11(120). doi:10.1126/sciimmunol.aea6419

BibTeX
@article{Bhagchandani2026,
  author = {Bhagchandani, Sachin H and Ehrenzeller, Stephen and Pires, Ivan S and Chaudhary, Namit and Booth, Carmen J and Kwon, Dong-Il and Koutsioumpa, Charalampia and Baker, Christopher A and Laxton, Claire and Santos Guedes de Sá, Keyla and Matthews, Cullen and Gill, Priya and Li, Sarah and Olszowka, Anna and Hudak, Andrew and Fischer, Suzanne and Bayarri-Olmos, Rafael and Hooper, William Brenham and Iwasaki, Akiko},
  title = {Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes},
  journal = {Science Immunology},
  year = {2026},
  volume = {11},
  number = {120},
  doi = {10.1126/sciimmunol.aea6419}
}
Kostenlos starten →